Endodomain truncation of the HIV-1 envelope protein improves the packaging efficiency of pseudoviruses

Zhang, Hui; Deng, Tingting; Fang, Qianjiao; Li, Shaoyong; Gao, Shuangquan; Jiang, Wen-ling; Chen, Gege; Yu, Kunyu; Zhou, Lizhi; Li, Tingting; Zheng, Qingbing; Yu, Hai; Li, Shaowei; Xia, Ningshao; Gu, Ying

doi:10.1016/j.virol.2022.07.003

Cited by 2 publications

(1 citation statement)

References 51 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Originally, the HIV packaging system only comprised of two plasmids, a backbone plasmid and an envelope plasmid. The pSG3Δenv and pNL4-3Δenv are examples of backbone plasmids (Bosch and Pawlita, 1990;Zhang et al, 2022). The essential genes are separated across 3 plasmids for second-generation systems and 4 plasmids for third-generation systems.…”

Section: The Human Immunodeficiency Virus (Hiv) Packaging Systemmentioning

confidence: 99%

Packaging systems for generating SARS-CoV-2 pseudoviruses: A mini review

Chin, J. W. T.,

Budiman, C.,

Teoh, P. L.

2023

MJM

View full text Add to dashboard Cite

The COVID-19 pandemic has caused a huge damage to global society, not only affecting health aspect but also economics. The development of effective vaccines and therapeutics has been a critical step in the fight against this pandemic, and much research has been committed to studying the causative virus, SARS-CoV-2. Pseudovirus, a valuable research tool that allows investigating SARS-CoV-2 in a safe and controlled environment, has gained significant attention in recent years. It is a promising tool for examining the behaviour of the viral envelope protein and the development of vaccines and therapeutics. Finding an optimized pseudovirus system is crucial for various scientific and medical research applications, especially in the study of viral infections, immune responses and vaccine development. It plays a crucial role in advancing our understanding of viral diseases to combat with the new variants. This minreview focuses on the concept of pseudovirus systems and factors affecting the pseudovirus yield.

show abstract

Section: The Human Immunodeficiency Virus (Hiv) Packaging Systemmentioning

confidence: 99%

Packaging systems for generating SARS-CoV-2 pseudoviruses: A mini review

Chin, J. W. T.,

Budiman, C.,

Teoh, P. L.

2023

MJM

View full text Add to dashboard Cite

show abstract

Biparatopic antibodies: therapeutic applications and prospects

Niquille,

Fitzgerald,

Gera

2024

mAbs

View full text Add to dashboard Cite

Biparatopic antibodies (bpAbs) bind distinct, non-overlapping epitopes on an antigen. This unique binding mode enables new mechanisms of action beyond monospecific and bispecific antibodies (bsAbs) that can make bpAbs effective therapeutics for various indications, including oncology and infectious diseases. Biparatopic binding can lead to superior affinity and specificity, promote antagonism, lock target conformation, and result in higher-order target clustering. Such antibody-target complexes can elicit strong agonism, increase immune effector function, or result in rapid target downregulation and lysosomal trafficking. These are not only attractive properties for therapeutic antibodies but are increasingly being explored for other modalities such as antibody-drug conjugates, T-cell engagers and chimeric antigen receptors. Recent advances in bpAb engineering have enabled the construction of ever more sophisticated formats that are starting to show promise in the clinic.

show abstract

Endodomain truncation of the HIV-1 envelope protein improves the packaging efficiency of pseudoviruses

Cited by 2 publications

References 51 publications

Packaging systems for generating SARS-CoV-2 pseudoviruses: A mini review

Packaging systems for generating SARS-CoV-2 pseudoviruses: A mini review

Biparatopic antibodies: therapeutic applications and prospects

Contact Info

Product

Resources

About